Amarin does not anticipate Hikma or Dr Reddy's to introduce generic Vascepa (icosapent ethyl) until the US Court of Appeals for the Federal Circuit decides on Amarin’s appeal over the generics sponsors’ patent-litigation victories – and only then with a “limited supply,” according to the originator’s president and CEO, John Thero.
Amarin Makes Vascepa Generics Prediction And Questions Supply
Federal Circuit Decision Anticipated Late 2020 Or Early 2021
Amarin – and the industry at large – was stunned in March this year when Hikma and Dr Reddy’s walked away from court with an invalidity ruling against six Vascepa patents in the US. The originator’s CEO gave an impassioned update on the current state of play, including the potential for generics to launch ahead of a Federal Circuit ruling later this year or early in 2021.
